Other Information
−Removed: Not Applicable.
−Removed: Exhibits - See exhibit index below.
+Added: - See exhibit index below.
Certificate of Increase of Series A Junior Participating Preferred Stock (incorporated by reference to exhibit 3.1 to the Company’s Quarterly report on Form 10-Q (No.
10 unchanged sentences
001-27072) for the period ended June 30, 2022).
−Removed: August 2, 2022 Second Amendment to Agreement of Sale and Purchase with Acellories, Inc.(incorporated by reference to exhibit 10.87 to the Company’s Quarterly report on Form 10-Q (No.
−Removed: 001-27072) for the period ended June 30, 2022).
−Removed: August 10, 2022 Termination agreement with Shenzhen Smoore Technology Limited (incorporated by reference to exhibit 10.88 to the Company’s Quarterly report on Form 10-Q (No.
+Added: August 2, 2022 Second Amendment to Agreement of Sale and Purchase with Acellories, Inc.
+Added: (incorporated by reference to exhibit 10.87 to the Company’s Quarterly report on Form 10-Q (No.
001-27072) for the period ended June 30, 2022).
7 unchanged sentences
001-27072) for the period ended September 30, 2022 filed November 14, 2022).
−Removed: December 5, 2022 Master Service Agreement between Sterling Pharma Solutions Limited and AIM ImmunoTech Inc.(incorporated by reference 10.93 to the Company’s Annual report on Form 10-K (No.
+Added: 5, 2022 Master Service Agreement between Sterling Pharma Solutions Limited and AIM ImmunoTech Inc.
+Added: (incorporated by reference 10.93
+Added: to the Company’s Annual report on Form 10-K (No.
001-27072) for year ended December 31, 2022).
13 unchanged sentences
001-27072) filed May 30, 2023).
+Added: September 20, 2023 Amended and Restated Material Transfer and Research Agreement with Roswell Park Cancer Institute Corporation d/b/a Roswell Park Comprehensive Cancer Center (incorporated by reference to Exhibit 10.1 to the Company’s Current Report of Form 8-K (No.
+Added: 001-27072) filed September 29, 2023).
Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 from the Company’s Chief Executive Officer.
2 unchanged sentences
Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 from the Company’s Chief Financial Officer.
−Removed: Inline XBRL Instance Document
−Removed: Inline XBRL Taxonomy Schema
−Removed: Inline XBRL Taxonomy Calculation Linkbase
−Removed: Inline XBRL Taxonomy Definition Linkbase
−Removed: Inline XBRL Taxonomy Label Linkbase
−Removed: Inline XBRL Taxonomy Presentation Linkbase
−Removed: Cover Page Interactive Data File (Embedded within the
−Removed: Inline XBRL document and included in Exhibit)
−Removed: Filed herewith.
+Added: XBRL Instance Document
+Added: XBRL Taxonomy Schema
+Added: XBRL Taxonomy Calculation Linkbase
+Added: XBRL Taxonomy Definition Linkbase
+Added: XBRL Taxonomy Label Linkbase
+Added: XBRL Taxonomy Presentation Linkbase
+Added: Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit)
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed
4 unchanged sentences
Financial Officer
−Removed: August 14, 2023
+Added: November 14, 2023
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.